drugset / Trial / NCT01033149
N-acetylcysteine in the Treatment of Bulimia Nervosa
NaSingle-groupOpen-labelTreatment
Summary
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of N-acetylcysteine (NAC) in the treatment on bulimia nervosa.
Timeline
- Start
- 2009-12
- Primary completion
- 2012-03
- Completion
- 2012-03
Outcome
Missed primary endpoint
paper NAC was not associated with significant reductions in frequency of binge-purge episodes PMID 23265409 ↗
Publications
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-acetylcysteine | Small molecule | 1200 mg | — |
| Subject | N-acetylcysteine | Small molecule | 2400 mg | — |